Cryoport Inc., a global provider of products and services to the cell and gene therapy industry, has entered into a strategic partnership with Cell and Gene Therapy Catapult, a company specializing in the advancement of cell and gene therapies, under which Cryoport Systems will establish its first global supply chain logistics center in the UK.

The GMP-compliant facility will be located at CGT Catapult’s large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre. The partnership will provide CGT Catapult collaborators, and the larger UK cell and gene therapy community, with access to Cryoport’s supply chain capabilities, including risk mitigation services and logistics support. 

“The cell and gene therapy industry has become an area of rapid growth in the U.K. with increasing governmental support, making now the prime opportunity to partner with CGT Catapult to offer advanced therapy manufacturers streamlined solutions for their cold chain logistics needs,” said Jerrell Shelton, CEO of Cryoport. “This partnership provides a valuable step in the expansion of our global supply chain infrastructure buildout to help accelerate the process of clinical development and commercialization of cell and gene therapies in the U.K. It also expands Cryoport Systems’ footprint and advances our longer-term plans in this region by starting with this initial foothold.”

Matthew Durdy, CEO of the Cell, and Gene Therapy Catapult, said, “Cryoport’s expertise in the logistics and supply chain needs of advanced therapy manufacturers is an invaluable addition to the life sciences ecosystem in Stevenage and the wider U.K. The services Cryoport offers will support the continued growth of the industry, by strengthening even further the established global supply chains from the U.K., and we look forward to the future success of Cryoport in the U.K.”